By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The University of California, San Francisco, and Optivia Biotechnology today said that they have received a $430,000 Phase I Small Business Innovation Research grant to develop a system for characterizing the role transporter proteins play in the disposition of drugs by the liver.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.